BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25647444)

  • 21. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype.
    Tseden-Ish M; Choi YD; Cho HJ; Ban HJ; Oh IJ; Kim KS; Song SY; Na KJ; Ahn SJ; Choi S; Kim YC
    Respirology; 2012 Jan; 17(1):127-33. PubMed ID: 21899657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer.
    Su D; Ma S; Liu P; Jiang Z; Lv W; Zhang Y; Deng Q; Smith S; Yu H
    Lung Cancer; 2007 May; 56(2):281-8. PubMed ID: 17222938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.
    Suk R; Gurubhagavatula S; Park S; Zhou W; Su L; Lynch TJ; Wain JC; Neuberg D; Liu G; Christiani DC
    Clin Cancer Res; 2005 Feb; 11(4):1534-8. PubMed ID: 15746057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.
    Tiseo M; Bordi P; Bortesi B; Boni L; Boni C; Baldini E; Grossi F; Recchia F; Zanelli F; Fontanini G; Naldi N; Campanini N; Azzoni C; Bordi C; Ardizzoni A;
    Br J Cancer; 2013 Apr; 108(8):1695-703. PubMed ID: 23549037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients.
    Yu D; Shi J; Sun T; Du X; Liu L; Zhang X; Lu C; Tang X; Li M; Xiao L; Zhang Z; Yuan Q; Yang M
    Tumour Biol; 2012 Jun; 33(3):877-84. PubMed ID: 22249976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy.
    Wang TB; Zhang NL; Wang SH; Li HY; Chen SW; Zheng YG
    Genet Mol Res; 2014 May; 13(2):3704-10. PubMed ID: 24854656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small-cell lung cancer.
    Rosell R; Manegold C; Moran T; Garrido P; Blanco R; Lianes P; Stahel R; Trigo JM; Wei J; Taron M
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S76-82. PubMed ID: 21885003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.
    Krawczyk P; Kucharczyk T; Kowalski DM; Powrózek T; Ramlau R; Kalinka-Warzocha E; Winiarczyk K; Knetki-Wróblewska M; Wojas-Krawczyk K; Kałakucka K; Dyszkiewicz W; Krzakowski M; Milanowski J
    J Cancer Res Clin Oncol; 2014 Dec; 140(12):2047-57. PubMed ID: 25028118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.
    Tan X; Wu Q; Cai Y; Zhao X; Wang S; Gao Z; Yang Y; Li X; Qian J; Wang J; Su B; Chen H; Han B; Jiang G; Lu D
    Clin Lung Cancer; 2014 Jan; 15(1):67-78.e12. PubMed ID: 24220096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
    Joerger M; deJong D; Burylo A; Burgers JA; Baas P; Huitema AD; Beijnen JH; Schellens JH
    Lung Cancer; 2011 Nov; 74(2):310-7. PubMed ID: 21529986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
    Sodja E; Knez L; Kern I; Ovčariček T; Sadikov A; Cufer T
    Eur J Cancer; 2012 Dec; 48(18):3378-85. PubMed ID: 22795264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients.
    Grenda A; Błach J; Szczyrek M; Krawczyk P; Nicoś M; Kuźnar Kamińska B; Jakimiec M; Balicka G; Chmielewska I; Batura-Gabryel H; Sawicki M; Milanowski J
    Cancer Med; 2020 Jan; 9(2):605-614. PubMed ID: 31797573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer.
    Muley TR; Sianidou M; Thomas M; Bischoff H; Dienemann H; Meister M; Schneider MA; Schnabel PA; Warth A
    Anticancer Res; 2014 Jul; 34(7):3707-13. PubMed ID: 24982391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer.
    Cheng J; Ha M; Wang Y; Sun J; Chen J; Wang Y; Tong C
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):231-8. PubMed ID: 22102173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh.
    Bushra MU; Rivu SF; Sifat AE; Nahid NA; Ahmed MU; Al-Mamun MMA; Apu MNH; Islam MS; Islam MR; Islam MS; Hasnat A
    Mol Biol Rep; 2020 Sep; 47(9):7073-7082. PubMed ID: 32880833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy].
    Wang J; Zhang Q; Zhang H; Wang Q; Yang X; Gu Y; Zhang S
    Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):337-41. PubMed ID: 20677561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer.
    Wei HB; Hu J; Shang LH; Zhang YY; Lu FF; Wei M; Yu Y
    Chin Med J (Engl); 2012 Aug; 125(16):2902-7. PubMed ID: 22932088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.